WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 326847
Description: Ozenoxacin, also known as GF-001001-00; M-5120; T-3912; GF-00100100, is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics.
MedKoo Cat#: 326847
Chemical Formula: C21H21N3O3
Exact Mass: 363.1583
Molecular Weight: 363.417
Elemental Analysis: C, 69.41; H, 5.82; N, 11.56; O, 13.21
Synonym: GF-001001-00; GF 001001-00; GF001001-00; M-5120; M5120; M 5120; T-3912; T 3912; T3912; GF-00100100; GF00100100; GF 00100100; Ozenoxacin; Xepi.
IUPAC/Chemical Name: 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
InChi Key: XPIJWUTXQAGSLK-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC(C)=C(NC)N=C4)=C3C)C1=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 363.417 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Koulenti D, Xu E, Mok IYS, Song A, Karageorgopoulos DE, Armaganidis A, Lipman J, Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019 Aug 18;7(8). pii: E270. doi: 10.3390/microorganisms7080270. Review. PubMed PMID: 31426596; PubMed Central PMCID: PMC6723731.
2: Schachner L, Andriessen A, Bhatia N, Grada A, Patele D. Topical Ozenoxacin Cream 1% for Impetigo: A Review. J Drugs Dermatol. 2019 Jul 1;18(7):655-661. Review. PubMed PMID: 31334625.
3: Clinical Review Report: Ozenoxacin 1% Cream (Ozanex): (Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539436/ PubMed PMID: 30942991.
4: Pharmacoeconomic Review Report: Ozenoxacin 1% Cream (Ozanex): (Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539347/ PubMed PMID: 30942989.
5: CADTH Canadian Drug Expert Committee Recommendation: Ozenoxacin 1% Cream (Ozanex — Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK539227/ PubMed PMID: 30933450.
6: Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R. Ozenoxacin: a review of preclinical and clinical efficacy. Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168. doi: 10.1080/14787210.2019.1573671. Epub 2019 Feb 11. Review. PubMed PMID: 30686133.
7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500961/ PubMed PMID: 30000020.
8: Wren C, Bell E, Eiland LS. Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018 Dec;52(12):1233-1237. doi: 10.1177/1060028018786510. Epub 2018 Jul 2. Review. PubMed PMID: 29962213.
9: Morimoto H, Kikukawa Y, Murakami N. Pharmacological profiles and clinical effects of ozenoxacin lotion for the treatments of acne vulgaris and superficial infection of the skin. Nihon Yakurigaku Zasshi. 2016 Jul;148(1):39-45. doi: 10.1254/fpj.148.39. Review. Japanese. PubMed PMID: 27430678.
10: Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35. Review. PubMed PMID: 25250996.